Effect of proton pump inhibitor therapy on serum vitamin B12 levels and hematologic parameters in the blood of patients with laryngopharyngeal reflux

Efecto de la terapia con inhibidores de la bomba de protones sobre los niveles séricos de vitamina B12 y los parámetros hematológicos en la sangre de pacientes con reflujo laringofaringeo

Abstract

Introduction: Laryngopharyngeal reflux (RLF) is an inflammation of the aerodigestive tract where the retrograde flow of gastric contents into the larynx and pharynx encounters the upper aerodigestive tract. Proton pump inhibitors (PPIs), especially Omeprazole, are often used to manage RLF. Some studies have shown that prolonged use of PPIs can result in anemia. Objective: To analyze the relationship of PPIs to serum Vitamin B12 and hematological parameters in RLF patients. Methods: This is an analytical study with a cross-sectional approach conducted at the Ear, Nose, and Throat (ENT) polyclinic of Dr. Wahidin Sudirohusodo Hospital, Makassar, by comparing vitamin B12 levels, hemoglobin, MCV, MCH, and MCHC before and after Omeprazole therapy for 3 months. Results: The study consisted of 20 RLF patients. There was a significant effect of Omeprazole therapy for 3 months on RSI and RFS scores (p<0.001 and p<0.001). There was no significant effect on Hemoglobin, MCV, MCH, and MCHC before and after Omeprazole therapy for 3 months (p=0.129; 0.694; 0.514; 0.847). There was no significant effect on vitamin B12 levels before and after Omeprazole therapy for 3 months (p=0.150). Conclusion: Omeprazole therapy for 3 months in patients with RLF does not affect vitamin B12 levels, hemoglobin, MCV, MCH, or MCHC.